Analysts Are Bullish on These Healthcare Stocks: IONS, KITE

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ionis Pharmaceuticals Inc (NASDAQ: IONS), Kite Pharma (NASDAQ: KITE) and Intra-Cellular Therapies (NASDAQ: ITCI) with bullish sentiments.

Ionis Pharmaceuticals Inc (NASDAQ: IONS)

In a report released yesterday, Joshua Schimmer from Piper Jaffray reiterated a Buy rating on Ionis Pharmaceuticals Inc (NASDAQ: IONS), with a price target of $51. The company’s shares closed yesterday at $38.38.

According to TipRanks.com, Schimmer is ranked 0 out of 5 stars with an average return of -10.5% and a 30.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Voyager Therapeutics Inc, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Ionis Pharmaceuticals Inc is Strong Buy and the average price target is $42, representing a 9.4% upside.

In a report issued on November 7, BMO Capital also reiterated a Buy rating on the stock with a $48 price target.
Kite Pharma (NASDAQ: KITE)

In a report released yesterday, John Newman from Canaccord Genuity reiterated a Buy rating on Kite Pharma (NASDAQ: KITE), with a price target of $75. The company’s shares closed yesterday at $49.61.

According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -16.9% and a 30.0% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Dimension Therapeutics Inc.

Kite Pharma has an analyst consensus of Strong Buy.

Intra-Cellular Therapies (NASDAQ: ITCI)

In a report released yesterday, Ritu Baral from Cowen & Co. reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ: ITCI), with a price target of $37. The company’s shares closed yesterday at $14.10, close to its 52-week low of $10.80.

Baral said:

“Today, ITCI reported 3Q16 results.”

According to TipRanks.com, Baral is a 2-star analyst with an average return of 0.0% and a 35.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Anthera Pharmaceuticals.

Currently, the analyst consensus on Intra-Cellular Therapies is Moderate Buy and the average price target is $29, representing a 105.7% upside.

In a report issued on November 1, RBC Capital also maintained a Buy rating on the stock with a $49 price target.